AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06125613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: In reality, there will not be 200 trials but 40, and no painful stimulus will be delivered. The objective is only to make the subject afraid of making a movement when the red stimulus appears, and for us to compare the situation afraid to move to that where there is no reason to be afraid in terms of corticocortical influences. The subject will then be invited, during the second experimental series, to perform the movements previously described. Whether the preparatory signal for movement is red or green, it will be followed with a delay of 500ms by a test stimulus alone (ST) or by a doublet of SC+ST stimulation. This stimulation will therefore occur during the motor programming period during which it has been shown in the literature that the pIPS exerts a facilitatory action on the primary motor cortex at a latency of 4 ms. In total, 10 ST and 10 SC-ST doublets will be delivered during the experimental series for each of the two colors, i.e. 40 stimulations in total.
Study NCT06309108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Booklet
Description: The education group was given training with a education booklet
Study NCT06309108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Reality Group
Description: The second of the intervention group was trained with augmented reality. Patients were able to see the augmented reality element with the 3DQR application.
Study NCT05651776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy, Exercise
Description: Outpatient physical therapy intervention incorporating golf related assessment of skills and prescribed exercises including postural, balance, and club swing
Study NCT04629703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib
Description: Fostamatinib (150 mg twice daily) for 14 days and Standard of Care
Study NCT04629703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (twice daily) for 14 days and Standard of Care
Study NCT06456632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Su Jok Therapy
Description: Su Jok Therapy
Study NCT06405503 — intervention group
Intervention type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION - OBSERVATIONAL ONLY
Study NCT05303779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Interventions of Eye Muscles
Description: Application of eye exercise for improving eye control post strabismus surgery
Study NCT05303779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medication and eye glasses
Description: medication and eye glasses used post strabismus surgery
Study NCT05303779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication and eye glasses
Description: medication and eye glasses used post strabismus surgery
Study NCT05776030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Speed Ergonomic Wheelchair
Description: Ergonomic wheelchair. The ergonomic wheelchair was developed by the MADE program and has anterior placed hand rims that are connected with a bicycle chain. In Aim 1, Participants will use the ergonomic wheelchair to test 3 different gear ratios.~1. 2:3~2. 1:1~3. 3:2
Study NCT05776030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Speed Ergonomic Wheelchair
Description: The multi-speed ergonomic wheelchair will be developed by the MADE program and will use a two-hand rim design so the participant can change gears by changing hand rims.
Study NCT05046054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous electrical nerve stimulation
Description: transcutaneous electrical nerve stimulation group received transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
Study NCT05046054 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transcutaneous electrical nerve stimulation
Description: Placebo transcutaneous electrical nerve stimulation group received no transcutaneous electrical nerve stimulation via two electrodes on the venous cannulation site 20 min before propofol injection
Study NCT05586594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B)
Description: Genetic testing for 4 MODY genes (GCK, HNF1A, HNF4A, HNF1B) to look for common non-syndromic MODY in Emirati population
Study NCT06150365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KSX01-TCRT cell therapy
Description: Patient autologous T cell therapy
Study NCT05204225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet Application
Description: Participants will receive a tablet app (ReHand) along with face-to-face physiotherapy sessions. The ReHand app includes an exercise program based on current scientific evidence for improving funcional ability and dexterity of the hand with neurological affectation. Those exercises are performed making controlled taps and movements while touching the touchscreen and guided by feedbacks. Also, ReHand app includes a prescription and monitoring web-based system for professionals. Along with this intervention, face-to-face physiotherapy sessions will be performed their respective centres.
Study NCT05204225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Participants of this group will receive a home exercise program on paper and face-to-face physiotherapy sessions. This intervention is the conventional approach usually delivered in their respective centres. Those exercises were specifically developed for the rehabilitation of the hand with neurological affectation.
Study NCT05177458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% maximum heart rate) for 30 minutes on a treadmill.
Study NCT05177458 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at 40-50% of maximum heart rate) for 30 minutes.
Study NCT06497244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro osteo-perforation
Description: the patient will receive miniscrew micro osteo-perforation in one side every month with molar distalization and the other side the distalization without micro osteo-perforation
Study NCT05311202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low-volume moderate-intensity group
Description: The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 20 minutes of two sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
Study NCT06143735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efgbemalenograstim alfa
Description: Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
Study NCT06143735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efgbemalenograstim alfa
Description: Efbemalenograstim alfa Injection is a recombinant fusion protein composed of the double molecules of human granulocyte colony-stimulating factor (G-CSF) and the Fc fragment of human immunoglobulin (hIgG2). It is used for adult patients with non-myeloid malignancies undergoing myelosuppressive anticancer therapy that is associated with a high risk of febrile neutropenia, to reduce the incidence of infections manifested by febrile neutropenia.
Study NCT05311202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-volume moderate-intensity group
Description: The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 30 minutes of three sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
Study NCT05311202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-volume moderate-intensity group
Description: The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 40 minutes of four sets of moderate intensity resistance exercise with 10 repetitions; (3) 5 minutes of cool down
Study NCT05311202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate-volume low-intensity group
Description: The interventional program will include (1) 5 minutes of warm-up and aerobic exercise from light to moderate intensity; (2) 35 minutes of four sets of low intensity resistance exercise with 20 repetitions; (3) 5 minutes of cool down
Study NCT05311202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: Reading a book related to cognitive function \& exercise for 40 minutes
Study NCT04738526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lithium disilicate (IPS e-max) ceramic crown
Description: monolithic lithium disilicate ceramic crown
Study NCT04738526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New gradient technology zirconia (5Y-TZP\ 3Y-TZP) IPS e.max ZirCad Prime ceramic crown
Description: conjunction with the two zirconium oxide raw materials 3Y-TZP and 5Y-TZP is responsible for producing a continuous, seamless progression of the shade and translucency within the material
Study NCT04738526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: natural tooth
Description: natural tooth is composed of enamel. Enamel is on the surface of every tooth and it has a natural hue of white. However, the underlying dentin layer has a slightly yellowish color. This yellowish hue shows through the enamel in almost everyone
Study NCT06378892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. The choice between Carboplatin or Cisplatin is entrusted to the clinician. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
Study NCT05786716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: An initial loading dose of 8 mg/kg body weight administered intravenously every 21 days followed thereafter by a maintenance dose of 6 mg/kg body weight.
Study NCT05786716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: An initial loading dose of 14 mg/kg administered intravenously every 21 days followed thereafter by a maintenance dose of 7 mg/kg.
Study NCT06130826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT06130826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06130826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06130826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06130826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive M5A-IL2 ICK SC
Study NCT06130826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06130826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06130826 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT04861987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS6422 and capecitabine
Description: PCS6422 is an experimental drug that, when combined with capecitabine, may make the immune response more active against cancer. Capecitabine is a commonly used oral fluoropyrimidine.
Study NCT05054608 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study. No intervention.
Study NCT06463288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jacobsons Breathing Technique
Description: Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
Study NCT06463288 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pranayama Technique
Description: Quality of life, cough and sputum analysis, spirometry, and shortness of breath were assessed.
Study NCT04716179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sperm test
Description: The semen sample will be collected and analyzed within an hour after collection.
Study NCT04716179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sperm test
Description: The semen sample will be collected and analyzed within an hour after collection.
Study NCT04716179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hormone levels (testosterone, FSH, LH, prolactin)
Description: Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
Study NCT04716179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: hormone levels (testosterone, FSH, LH, prolactin)
Description: Hormone levels (testosterone, FSH, LH, prolactin) will be assessed on 5-7 days after symptom onset until the end of hospital stay.
Study NCT04716179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SARS-CoV-2 Ig G levels
Description: SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
Study NCT04716179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Ig G levels
Description: SARS-CoV-2 Ig G levels will be assessed on 3 months after discharge
Study NCT04716179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Testis pathology samples
Description: Postmortem examination of the testes of patients deceased as a result of COVID-19 infection will be carried out using immunohistochemistry analysis.
Study NCT06578988 — intervention group
Intervention type: PROCEDURE
Intervention: Mammography Images
Description: Ultrasound and / or mammography are typically performed and reported by the imaging team at the same visit, with biopsy performed when indicated. This service is an important part of cancer care provision, with approximately half of the breast cancers diagnosed presenting via the symptomatic service rather than identified at screening.
Study NCT05140161 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen
Description: use of hemostatic device in order to reduce bleeding in nail surgery
Study NCT05224921 — intervention group
Intervention type: OTHER
Intervention: Not applicable (cohort study)
Description: This is a prospective observational study and does not include interventions. The exposure is peripheral perfusion index and the outcome is the incidence of late onset sepsis. From the day when the very low birth weight infant is admitted into hospital, PPI monitoring should be recorded once a day, and continuous monitoring would be recorded until 1 month after birth. Before collection, the infant will be confirmed to be in supine position with neutral temperature, and at the same time, the infant will be in a quiet state, without the contact and operation of medical personnel.
Study NCT04790305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
Study NCT04779619 — intervention group
Intervention type: OTHER
Intervention: Online self-report questionnaire completion
Description: After reading the PIS and completing the consent page on Qualtrics participants will then be presented with the demographic, PHQ-9, GAD-7 and BSL-23 questionnaires which will be used to determine later allocation of their data to one of the three group. They will then be presented with the PERCI, FFMQ-15 and DERS.
Study NCT06192381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Learning Module (WBL)
Description: To ensure a uniform starting point, the participants were recruited via faculty website and students' academic counseling services. At the baseline, after the initial assessment, the participants were randomized at a 1:1 allocation ratio into the following groups: 1) traditional health education group (control group) (n = 68) who received health education with traditional face-to-face method; 2) web-based health education group (intervention group) (n = 68) who received health education with Web-Based Learning Module (WBL).
Study NCT04784429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kenevo or C-Leg 4
Description: Kenevo fitted to subjects walking slower than 0.8 m/s as measured by the 2-minute Walk Test. C-Leg 4 fitted to subjects walking faster than 0.8 m/s.
Study NCT04784429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non microprocessor controlled knee (NMPK)
Description: NMPK consistent with current standards of care
Study NCT06413901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIP
Description: TIP hypospadias repair
Study NCT05236439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interposition supraciliary implant
Description: Surgical placement of SV22 interposition supraciliary implant in the supraciliary space
Study NCT04730570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother
Description: Essential Coaching for Every Mother consists of 53 standardized text messages that provide evidence-based information that women should be aware of related to caring for their newborn and maternal mental health. Messages are personalized with the name of the child. Messages sent from birth to six-weeks postpartum, with two messages sent per day in the first two weeks and a daily message for weeks 3-6. The following topics covered in Essential Coaching for Every Mother include anxiety, depression, maternal self-care, postnatal follow-up, breastfeeding or formula feeding, infant concerns, cord care, well-baby care, normal development, crying, and safe sleep. Women who receive the messages will be able to self-select breastfeeding or formula feeding messages.
Study NCT05127122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Description: Injectable
Study NCT06560047 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Catheter ablation
Description: Catheter ablation with pulmonary vein isolation will be the study intervention. Patients randomized to the intervention arm will undergo catheter ablation within six weeks of randomization. In the waiting-time for ablation, patients will receive standard treatment for AF and HF, as per current guideline recommendations. Catheter ablation will be performed at one of six high-volume ablation centers in Denmark. Mode of catheter ablation will be at the discretion of the operator. Radiofrequency ablation, cryo-balloon ablation and pulsed-field ablation will be utilized. The treating physician should ensure successful pulmonary vein isolation after ablation with either post-procedural mapping or pacing, as per current standards. Only pulmonary vein isolation will be performed during the ablation procedure.
Study NCT06388499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECC (Telerehabilitation and Exercise for Chronic Conditions)
Description: Exercise: Synchronous group exercise sessions will be delivered weekly via videoconferencing by a physiotherapist. Recordings of exercise sessions will be made available. Participants will be advised to perform additional exercise sessions at their own convenience to supplement the synchronous exercise sessions and facilitate adherence to physical activity guidelines.~Education: A synchronous educational webinar will be delivered each week. These will be delivered by relevant healthcare professionals and explore various aspects of self-management of health and well-being. Recordings of the webinars will be made available to participants.~Social component: At the end of each weekly synchronous group exercise session, participants will have the opportunity to engage in a 10-15-minute synchronous online social interaction with other participants in their exercise group via videoconferencing.
Study NCT06576271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4527363
Description: GSK4527363 will be administered to participants.
Study NCT06576271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching GSK4527363
Description: Placebo matching GSK4527363 will be administered to participants.
Study NCT06576271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be administered to participants.
Study NCT04727151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAC01-HER2
Description: TAC01-HER2 and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide
Study NCT04727151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAC01-HER2 plus pembrolizumab
Description: TAC01-HER2 plus pembrolizumab and:~* fludarabine and cyclophosphamide, or~* clofarabine and cyclophosphamide, or~* bendamustine, or~* cyclophosphamide